vaccines could be available by the middle of 2021 if they win regulatory approval, but their inventors need patent protection, the head of the global pharmaceutical industry group said.Covid-19 vaccines by American pharmaceutical giant Pfizer and its German partner BioNtech, as well as Moderna and AstraZeneca have shown promising results in large clinical trials, but there is no question of "cutting corners", said Thomas Cueni, director-general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)."So far 3 we have 3 out of 3 were hits.
I would expect that we will see something similar with Johnson & Johnson, I would expect that we would see similar positive results with Novavax, and many others, Sanofi.